Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Published:2016-11-14 Issue:1 Volume:6 Page:49-57
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Ahamadi M¹,Freshwater T¹,Prohn M²,Li CH¹,de Alwis DP¹,de Greef R³,Elassaiss-Schaap J⁴,Kondic A¹,Stone JA¹

Affiliation:

1. Merck & Co., Inc; Kenilworth New Jersey USA

2. Former employee of Merck, currently employed at qPharmetra; Nijmegen The Netherlands

3. Former employee of Merck, currently employed at Quantitative Solutions, a Certara company; Oss The Netherlands

4. Former employee of Merck, currently employed at PD-Value; Houton The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Reference18 articles.

1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat. Rev. Cancer,2012

2. The PD-1 pathway in tolerance and autoimmunity;Francisco;Immunol. Rev.,2010

3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010

4. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N. Engl. J. Med.,2011

5. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors;Curran;Proc. Natl. Acad. Sci. USA,2010

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab;Clinical Pharmacology & Therapeutics;2024-07-22

2. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

3. A cost comparison of pembrolizumab: Fixed and weight-based dosing;Journal of Oncology Pharmacy Practice;2024-05-23

4. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma;Scientific Reports;2024-05-16

5. Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy;Cancer Chemotherapy and Pharmacology;2024-03-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3